On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
L’expertise universitaire, l’exigence journalistique
Articles sur Moderna vaccine
Affichage de 1 à 20 de 58 articles
The FDA’s authorization of COVID-19 shots for children ages 6 months to 4 years will bring relief for millions of parents. Pending CDC endorsement, shots for this group will be available within days.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
New data on the second booster suggests the older you are, the more you need it.
Parents can now choose Moderna to vaccinate their children against COVID. So how effective is it, and how does it compare with Pfizer?
Some of the omicron variant’s unique properties – such as its ability to spread rapidly while causing milder COVID-19 infections – could usher in a new phase of the pandemic.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
There’s not enough evidence yet to support the AstraZeneca CEO’s statement. But it is theoretically plausible.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
Before the pandemic, the public perceived science as infallible and inaccessible. But the opening up of research to the general public has changed that perception.
Thanks to the collaborative efforts of governments, funding agencies, academia, biotech and pharmaceutical companies, large-scale manufacturing of mRNA drug products is becoming a reality.
A medical student answers questions he gets asked at a COVID-19 vaccine clinic: Efficacy versus real-world effectiveness, immune response and how the mRNA vaccines compare to vaccines already in wide use.
As we continue to roll out COVID-19 vaccines around the world, we’re learning people who are immunocompromised aren’t necessarily protected as well from the first two doses.
An infectious disease doctor explains the science behind COVID-19 vaccines at a level that children – and adults – of all ages can understand.
Trials are under way to ascertain whether COVID vaccines are safe and effective for children under 12. In the meantime, it’s reassuring to note that generally, young kids cope OK with the virus.
The federal government has announced the Pfizer vaccine will be available to all Australians from August 30. Though there may well be long waits.
While emergency use authorization gets vaccines out to the public more quickly, it doesn’t skip any steps that full approval requires.
Doses of the Moderna vaccine will be available in Australia from mid-September. So if you’re in an eligible group you could be offered either Pfizer or Moderna. Here’s how they compare.
Les contributeurs les plus fréquents
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor, Biology, York University, Canada
-
Instructor of Human Immunology, Emory University
-
Professor of Microbiology, School of Medicine, University of Washington
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh Health Sciences
-
Leader, Science Communication Teaching Program, The University of Melbourne
-
Associate Professor, Epidemiology, Deakin University
-
Director, Center for Public Interest Communications, University of Florida
-
Professor of Law, Saint Louis University
-
Professor and Chair in Integrative Studies, UMass Amherst
